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ABSTRACT  
 
Hemorheological Approach for Early Detection of Diabetic 
Nephropathy 
 
Seohui Lee 
 
Department of Medicine  
The Graduate School, Yonsei University  
 
(Directed by Professor Chul Woo Ahn ) 
 
 
Background: Hemorheologic alterations or changes in blood viscosity 
have been suggested to play a role in the pathogenesis of diabetic 
microvascular complications. We measured various hemorheologic 
parameters in type 2 diabetes patients at different stages of chronic kidney 
disease (CKD) and assessed their possible role as early markers of 
diabetic nephropathy and renal insufficiency. 
Methods: One hundred-five patients with type 2 diabetes were divided 
into four groups according to glomerular filtration rate (GFR). 
Hemorheologic parameters, including erythrocyte deformability, 
fibrinogen/elongation index (EI), and aggregation index (AI) were 
measured using microfluidic hemorheometer. Various metabolic 
parameters were assessed from fasting blood samples and urine 
albumin/creatinine ratio (ACR) was calculated from first morning voided 
urine. 
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Results: There were significant differences in RBC deformability, AI, 
critical stress, fibrinogen/EI, and albumin/creatinine ratio among patients 
in different stages of CKD (all p<0.05), RBC deformability and 
Fibrinogen/EI significantly differed between normal and CKD 2 patients 
while there was no such difference in ACR. In multiple regression 
analysis, Fibrinogen/EI at 3Pa was an independent predictor of GFR 
(ß=-0.328, p<0.05). Also, AI, critical stress, and CSS/EI at 3 Pa, 
CSS*ESR were significantly different among patients at different stages 
of diabetic nephropathy, with a significant difference in CSS*ESR 
between normal and microalbuminuric patients (all p< 0.05).  
Conclusions: CSS*ESR are sensitive parameters measured via 
point-of-care testing for detecting erythrocyte alterations in early CKD 
and nephropathy in patients with type 2 diabetes. Further studies are 
warranted to verify their use as screening tools for diabetic nephropathy 
and renal impairment. 
 
 
 
 
 
 
 
------------------------------------------- 
Key Words : diabetic nephropathy, hemorheololgic parameter, 
RBC deformability, GFR, Albumin-creatinine ratio 
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I. INTRODUCTION 
The worldwide pandemic of diabetes and the subsequent complications 
present major threats to the community health. Diabetic complications 
consist mainly of vascular diseases, such as microangiopathy and 
macroangiopathy, and they have been shown to be closely associated with 
hemorheological abnormalities such as elevated whole blood viscosity1. 
Hemorheological alterations were reported in present in patients with new 
onset diabetes 1, 2, and other studies suggested that it may precede the 
development of diabetic microangiopathy1, 3. Therefore, hemorheological 
disturbances seem to occur in the early phase of disease progression2, 4.  
Among factors determining blood viscosity including hematocrit, plasma 
proteins such as fibrinogen, red blood cell (RBC) deformability, and RBC 
aggregation5, 6, previous research was mainly focused on the correlations 
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between diabetic nephropathy and erythrocyte deformability and 
aggregation. According to a recent study, all of these factors are 
intimately connected to one another, and whole blood viscosity is 
determined not only by these individual factors, but also by their 
interactions 7. These changes in whole blood viscosity may in turn play 
important roles in the pathogenesis of vascular complications associated 
with diabetes mellitus.  
In order to prevent the progression of diabetic complications, an early 
detection is crucial. Especially, for patients with diabetic nephropathy 
(DN) treated with optimal therapy at an early phase, the disease can be 
slowed or prevented from progressing to chronic kidney disease (CKD)8. 
Currently, diabetes patients are encouraged to undergo regular urinary 
analyses, ultrasonography, and blood examinations to screen for diabetic 
nephropathy. However, this requires high costs and demands patient 
compliance, and thus regular checkups for diabetic complications are 
difficult in clinical settings. Moreover, although an increased excretion of 
urinary albumin is considered a golden standard for detecting the onset 
and progression of diabetic nephropathy9, it has several limitations. 
Therefore, more simple and reliable biomarkers with higher sensitivity 
and specificity are needed for early prediction of the onset and monitoring 
of the progression of DN 10  
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In our previous study, there were significant differences in the degree of 
RBC deformability when comparing diabetes patients with healthy control, 
and also between diabetes patients with chronic renal disease or end stage 
renal disease and those with normal renal function11. Hemorheologic 
alterations are assessed by point-of-care testing with 5 μL of whole blood 
within 30 seconds, and there is a need for discovering a more sensitive 
marker for early diabetic nephropathy. To our knowledge, the present 
study is the first study concerning the association between diabetic 
nephropathy and hemorheology in comparison with the 
albumin/creatinine ratio (ACR). 
In this study, we plan to assess novel markers of hemorheologic 
disturbances and validate these parameters by comparing with urine 
albumin creatinine ratio for the early detection of diabetic nephropathy 
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II. MATERIALS AND METHODS 
1 Subjects  
One hundred-five type 2 diabetes mellitus patients were enrolled in this 
study. Diabetes was defined as both previously diagnosed and 
undiagnosed type 2 diabetes mellitus. Diagnosed diabetes mellitus was 
based on self-reported responses. The diagnosis of diabetes was based on 
the following American Diabetes Association criteria: fasting plasma 
glucose (FPG) ≥126 mg/dL (7.0 mmol/L), or symptoms of diabetes plus 
casual plasma glucose ≥200 mg/dL (11.1 mmol/L), or 2-h postload 
glucose ≥200 mg/dL (11.1mmol/L) during a 75-mg oral glucose tolerance 
test; or glycated hemoglobin (HbA1C) ≥ 6.5% (47.5 mmol/mol).  
The subjects were divided into four groups according to their glomerular 
filtration rate (GFR), calculated using the Modification of Diet in Renal 
Disease (MDRD) formula as follows: 186 x (creatinine)-1.154 x (age)-0.203 x 
(0.742 if female) x (1.210 if black). Seventy-nine subjects were classified 
as healthy controls (GFR >90 mL/min/1.73 m2 without proteinuria); 19 
patients had mild CKD (CKD stage 2: GFR, 60-89 mL/min/1.73 m2); 13 
subjects had moderate CKD (stage 3 ~ 5 : GFR < 60 mL/min/1.73 m2). 
Women who were pregnant or lactating; and subjects with anemia, acute 
illness, cancer, abnormal liver function, or other conditions, including any 
red blood cell disorders, not suitable for study entry according to the 
researchers’ judgment were excluded from the study.  
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All participants gave the informed consent, and the study was approved by 
the Institutional Review Board of Gangnam Severance Hospital. 
 
2. Design 
This study is a cross-sectional study, in which all data and samples were 
collected at a baseline visit, and includes patients from the Gangnam 
severance hospital, an 800-bed tertiary care center in Korea. Patient 
information was obtained from all patients with diabetes by a standardized 
questionnaire.  
 
3. Measurements 
Anthropometric and biochemical measurements 
Body weight and height were measured in the morning with light clothing 
without shoes. Body mass index (BMI) was calculated as body weight in 
kilograms divided by height in meter squared (kg/m2). Blood pressure 
was measured twice in the sitting position and a mean value was 
calculated. Fasting blood samples were drawn and analyzed for HbA1C, 
serum glucose, cholesterol, triglycerides, HDL and LDL cholesterol, 
blood urea nitrogen (BUN), creatinine, triglyceride, fibrinogen, 
hemoglobin (Hb), and the erythrocyte sedimentation rate (ESR). The urine 
ACR was determined centrally from first voided morning urine in all 
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patients. Renal function was calculated using the MDRD formula as 
described above. 
 
4. Sample preparation and measurement techniques for 
hemorheologic parameters 
Blood samples were drawn from the antecubital vein into 
EDTA-containing vacutainers. All analyses were completed within 8 
hours of fasting blood collection.  
The erythrocyte deformability and aggregation were measured by using a 
microfluidic hemorheometer (RheoScan-AnD300), RheoMeditech, Seoul, 
Korea). For deformability measurements, the erythrocyte suspension in 
high viscous medium (polyvinylpyrrolidone solution) was driven by 
differential pressure through a microchannel. During the flow, a laser 
beam (wavelength, 635 nm) from a laser diode of power 1.5 mW passed 
through the diluted erythrocyte suspension. The diffraction pattern of the 
flowing erythrocytes at plural shear stresses was projected onto a screen, 
captured by a charge-coupled device-video camera, and finally analyzed 
by computer. The elongation index (EI) of the erythrocytes was defined 
as: (L − W) / (L + W), where L and W are the major and minor axes of the 
ellipse, respectively. And The elongation index (EI) in RBCs exposed to 
shear stress (3 Pa) was used to assess deformability. 
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Critical shear stress (CSS) was measured using native whole blood 
without adjusting for hematocrit. Critical shear stress was defined as the 
minimum shear stress required to disperse RBC aggregates. For the CSS 
measurement, a transient microfluidic technique was adopted with optical 
detection. When a whole blood sample stored in a reservoir chamber was 
driven by a pressure differential through a narrow micro-channel (K-01, 
Rheomeditech, Seoul, Korea), the pressure differential exponentially 
decreased with time and the flow ceased asymptotically. During the 
process, the time-varying backscattered light intensity and pressure data 
were recorded in a computer data file and analyzed. When the 
backscattered light yielded a maximum, the corresponding time and shear 
stress were determined as critical time and critical shear stress, 
respectively. Further details of this technique are provided elsewhere 12. 
To assess erythrocyte aggregation, blood samples were perfused to a 
microchip, and a magnetic rotating mechanism was used to stir the 
suspension in order to induce shear flow to disaggregate the RBCs. A light 
signal transmitted through the blood sample was detected by a photodiode, 
and all data were analyzed by computer . 
 
5. Statistical analysis  
Statistical analysis was performed using SPSS version 20 (SPSS Inc., 
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Chicago, IL, USA). The baseline characteristics are expressed as means ± 
standard deviations for continuous variables, and frequencies for 
categorical variables. The statistical significance of differences in 
categorical variables between groups was tested using the χ2 test. 
Statistical differences between the four groups were assessed using 
one-way ANOVA, with all differences considered significant at p<0.05. 
And we used multiple and logistic regression for show association GFR 
and orther hemorheologic parameter. 
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III. RESULTS 
 
1. Baseline characteristics 
The participants were divided into 3 groups according to GFR. For 
comparing the baseline characteristics of the groups, clinical data were 
obtained and analyzed. There were no significant difference among the 
groups in terms of sex, systolic blood pressure (SBP), HbA1c, fasting 
plasma glucose, hemoglobin, fibrinogen, urine ACR, ESR, BMI, total 
cholesterol, LDL and HDL cholesterol, triglycerides, fibrinogen, BUN, 
and creatinine. Urine ACR, ESR, Hb, fibrinogen, BUN, and creatinine 
were significantly different among the groups (p<0.05 for all; Table 1) 
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Table 1. Baseline characteristics of the patients (N=105) 
 
 
 
 
 
 
 
 
 
GFR > 90 
mL/min/1.73 m2 
(N=73) 
GFR 60~90 
mL/min/1.73 m2 
(N=19) 
GFR < 60 
mL/min/1.73 m2 
(N=13) 
P-value 
Age, years 
Sex (female, %) 
BMI (kg/m2) 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
HbA1c(%) (mmol/mol) 
FPG ( mg/dL ) 
Urine ACR (mg/mmol) 
T. cholesterol (mg/dL) 
Triglyceride (mg/dL) 
HDL ( mg/dL ) 
LDL (mg/dL) 
ESR (mm/h) 
Hb (g/dL) 
Fibrinogen ( mg/dL ) 
Creatinine ( mg/dL ) 
BUN ( mg/dL ) 
 
57.8 
41.1 
24.24 
122 
73 
7.4 (57) 
149 
9.86 
121.99 
121.9 
51 
103.3 
14.96 
14.08 
271.59 
0.90 
14.33 
 
62.5 
47.4 
25.4 
123 
74 
9.2 (77) 
216.95 
272.63 
171.16 
173 
44.3 
90.5 
26.56 
13.53 
315.47 
0.99 
19.1 
 
56.6 
50 
25.79 
135 
75.9 
8.1 (53) 
151 
2518.0 
194.46 
160.54 
46.08 
107.15 
47.08 
12.5 
385.7 
1.69 
26.8 
 
0.124 
0.856 
0.124 
<0.001 
0.287 
0.22 
0.23 
<0.001 
0.338 
0.026 
0.758 
0.268 
<0.001 
0.007 
<0.001 
<0.001 
<0.001 
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2. Correlations between hemorheologic parameters and GFR 
Participants were divided into 3 groups according to their GFR for 
comparison of the hemorheologic parameters. The elongation index, 
which indicates the RBC deformability, showed a gradual decrease with 
the deterioration of GFR (Table 2), and a significant reduction in 
erythrocyte deformability was observed between the mild CKD group and 
the healthy controls (0.314 ± 0.006 vs. 0.320 ± 0.002, p<0.05; Table 2). 
The aggregation index, which indicates the RBC aggregation, tended to 
show an inverse relationship with GFR (p=0.080; Table 2), whereas 
critical shear stress showed a significant difference between 
CKD(GFR<60) and healthy controls (393.64 vs. 267.97, p<0.05; Table 2). 
CSS/EI at 3 Pa, CSS/EI at Max, CSS*SS 1/2 significantly differed 
between the moderate CKD groups and the healthy controls (p<0.05; 
Table 2). Furthermore, CSS*ESR was found to significantly differ 
between the moderate CKD and mild CKD groups, as well as between the 
mild CKD and the healthy control groups (p<0.05 for all). In multiple 
regression analysis, CSS*ESR was an independent predictor of GFR in a 
model adjusted with BMI, Hb, ESR , and age(ß = -0.328 , p < 0.05).  
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Table 2. Hemorheologic parameters in different stages of chronic kidney 
disease. 
 
 
GFR < 60 
mL/min/1.73 m2 
(N=13) 
GFR 60~90 
mL/min/1.73 m2 
(N=19) 
GFR > 90 
mL/min/1.73 m2 
(N=73) 
P-value 
RBC 
deformability 
(EI at 3 Pa) 
0.313 ± 0.020 0.314 ± 0.006* 0.320 ± 0.002 0.047 
Aggregation 
index 
44.77 ± 6.34 41.94 ± 5.74 39.76 ± 5.61 0.027 
Critical stress 393.64 ± 180.31 298.66 ± 74.20 267.97 ± 121.12 0.008 
CSS*ESR 21345.13 ± 4878.54§ 8585.34 ± 2091.24*  4655.42 ± 720.87 <0.001 
CSS/EI at 3 Pa 1289.16±683.03§ 987.98 ± 264.68 845.73 ± 405.93 0.003 
CSS/EI Max 695.29 ± 86.78§ 530.89 ± 134.36 477.48 ± 213.49 0.05 
CSS*SS1/2 1001.67 ± 628.83§ 752.50 ± 248.39 619.31 ± 330.55 0.03 
ESR 48.08 ± 23.34§ 26.58 ± 23.72* 14.96 ± 14.85 <0.001 
Fibrinogen 374 ± 69.09§ 315 ± 103.3 271.5 ± 57.7 <0.001 
Data are mean ± SD. Comparison among the groups according to GFR was done using 
ANOVA and posthoc analysis 
GFR, glomerular filtration rate; RBC, red blood cell; EI, elongation index; ESR, 
erythrocyte sedimentation rate; SS1/2, Shear stress 1/2 
*P <0.05 between GFR>90 and GFR 60~90 
§P < 0.05 between GFR>90 and GFR <60 
 
3. Factors assoacited with hemorheologic parameters 
Fibrinogen, which affects the aggregation index, also showed significant 
inverse correlations with GFR (p<0.05, Table 1). Fibrinogens and AI 
showed similar tendencies, with fibrinogen significantly differing between 
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moderate CKD patients and healthy controls. Moreover, critical shear 
stress tended to increase with the rate of fibrinogen, and it showed a 
similar tendency to the aggregation index, with a significant difference 
observed between moderate CKD and healthy controls (411.27 vs. 267.97, 
p<0.05, Table 1). In addition, RBC deformability, namely the elongation 
index at 3 Pa, was compared among patients in tertiles according to 
HbA1c level (HbA1c ≤ 7.0% vs. 7.0 < HbA1c ≤ 9.0% vs. HbA1c > 9.0%). 
RBC deformability decreased gradually in the order of increasing HbA1c 
(0.324 ± 0.014 vs. 0.317 ± 0.021 vs. 0.304 ± 0.021, respectively, p < 
0.001). This finding is consistent with the well-known concept of 
decreased RBC deformability in hyperglycemic condition.  
 
4. Correlations between urinary albumin creatinine ratio and 
hemorheologic parameters 
ACR showed a significant inverse correlation with GFR (p<0.05). ACR 
differed significantly between the moderate CKD group and healthy 
controls (p <0.05), but not between the mild CKD group and healthy 
controls (Figure 1). Significant correlations were observed between 
various hemorrhologic parameters including AI, Critical stress, CSS/EI at 
3Pa, CSS/EI at Max, CSS*SS1/2, CSS*ESR, ESR and urine ACR (r2 = 
0.452, 0.285, 0.253, 0.248, 0.255, 0.321 and 0.246; P < 0.001, 0.009, 
16 
 
0.009, 0.011, 0.01, 0.001 and 0.05, all respectively,). Serum fibrinogen 
was also in a positive correlation with urine ACR (r2 = 0.426, P < 0.001).  
When subjects were divided into normal, microalbuminuria, and 
macroalbuminuria groups according to ACR, there wase significant 
differences in Fibrinogen/EI at 3 Pa between normal and microalbumiria 
group (Table 3, P=0.003). 
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Table 3. Hemorheologic parameters in different stages of diabetic 
nephropathy 
 
 
Data are mean ± SD. Comparison among the groups according to GFR was done using 
ANOVA and posthoc analysis. 
Abbreviations : ACR, albumin/creatinine ratio; EI, elongation index 
*P <0.05 between ACR>30 and ACR 30~300 
§P < 0.05 between ACR 30~300 and ACR>300 
¶ P < 0.05 between ACR<30 and ACR >300 
 
 
 
 
 
ACR < 30 
mg/mmol 
(N=77) 
ACR 30~300 
mg/mmol 
(N=12) 
ACR > 300 
mg/mmol 
(N=16) 
p-value 
AI 99.73 ± 5.51 43.53 ± 6.15 43.71 ± 6.41¶ 0.01 
Critical stress 266.96 ± 188.24 322.26 ± 66.05 370.65 ± 173.99¶ 0.008 
EI at 3Pa 0.318 ± 0.021 0.308 ± 0.027 0.316 ± 0.02 0.23 
CSS * ESR 856.01 ± 195.89 1104.89 ± 381.13* 1170.65 ± 261.63§¶ <0.001 
CSS/EI at 3 Pa 4243.18 ± 685.96  12658.81 ± 3401.64 17420.23 ± 4181¶ 0.006 
CSS/EI at max 475.31 ± 208.43 576.05 ± 119.41 654.41 ± 302.91¶ 0.008 
CSS*SS 1/2 623.32 ± 327.33 788.23 ± 230.25 942.18 ± 590.06¶ 0.006 
ESR 14.7 ± 1.65 37.75 ± 8.54* 39.81 ± 5.62 <0.001 
18 
 
 
Figure 1. Urine albumin/creatinine ratio (ACR) in different stages of CKD. 
ACR differed significantly between CKD 3 group and healthy controls, 
but no such difference was observed between the CKD 2 group and 
healthy controls. 
*P-value < 0.05 
A: GFR <60 mL/min/1.73 m2 
B: GFR 60~90 mL/min/1.73 m2 
D: GFR > 90 mL/min/1.73 m2 
GFR, glomerular filtration rate 
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IV. DISCUSSION 
In present study, we demonstrated significant differences in several 
hemorheologic parameters in different stages of CKD and diabetic 
nephropathy in patients with type 2 diabetes, and it was valid in 
differentiating patients with mild CKD from normal renal function as well 
as microalbuminuria from normal. Hemorheologic alterations showed 
close linear relationships to urinary albumin creatinine ratio.  
More than 50 years have passed since Skovborg et al. first studied blood 
viscosity in diabetic patients 13. Since then, many researchers have 
reported that blood viscosity is significantly increased in diabetic patients, 
and there have been numerous studies on the correlations between 
erythrocyte deformability and diabetic microangiopathies. For example, 
Brown et al. reported an association between reduced erythrocyte 
deformability and diabetic nephropathy 14. They demonstrated greater 
impairment of erythrocyte deformability in patients with diabetes with 
normal renal function compared with non-diabetic controls. Subsequently, 
more severe impairment in erythrocyte deformability was noted in 
patients with diabetic nephropathy. 
Elevated blood viscosity in patients with diabetes can be explained by an 
increase in erythrocyte aggregation and a decrease in erythrocyte 
deformability. Hyper-aggregation of erythrocytes increases low-shear 
viscosity, whereas decreased cell deformability increases high-shear 
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viscosity. Generally, hyperglycemia leads to membrane glycation, which 
stiffens the erythrocyte membranes. In turn, the stiffened membranes 
reduce cellular deformability, which is frequently observed in local 
hypoxia and microangiopathies, potentially resulting in the development 
of diabetic nephropathy . 
Currently, diabetic nephropathy is divided into subgroups according to the 
urine ACR, and the progression of DN is estimated by urinary analysis 
(ACR and protein/creatinine ratio), blood sampling (GFR, creatinine), and 
renal sonography. In the early, microalbuminuria stage, the progression of 
nephropathy can be reversed if the proper management is started in time, 
emphasizing the importance of early detection and diagnosis of this 
disorder. 
However, there is currently no tool allowing easy, point-or-care testing for 
the early diagnosis for DN. Moreover, the degree of albuminuria is not 
necessarily linked to disease progression in patients with diabetic 
nephropathy secondary to either type 1 or type 2 diabetes 15. This was 
illustrated in a report of 79 patients with type 1 diabetes from the Joslin 
Kidney Study, who were followed for a mean of 12 years after the onset of 
moderately increased albuminuria 9. Twenty-three of the patients 
progressed to advanced disease (GFR <60 mL/min). Among these patients, 
11 had either stable moderately increased albuminuria or regression to 
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normal albuminuria. Presently, the factor(s) responsible for progressive 
GFR decline in nonalbuminuric diabetic nephropathy are not known. 
Therefore, there is a need for a new marker that can detect 
microalbuminuria as well as early renal impairment.  
In our study, the patients were classified according to their GFR, which 
represents the actual renal function. The GFR, which is the volume of 
fluid filtered from the renal glomerular capillaries into the Bowman's 
capsule per unit time, is clinically important because it represents an 
accurate measurement of renal function 11. Moreover, blood urea nitrogen 
and creatinine are not raised above the normal range until 60% of total 
kidney function is lost. 
Our study results showed that renal function was associated with not only 
RBC deformability, aggregation index, and critical stress, but also with 
ESR and fibrinogen. ESR is known to be frequently elevated in patients 
with renal insufficiency, and accordingly, we found that the elevation of 
ESR was higher when the renal insufficiency was more severe. Fibrinogen 
has been previously demonstrated to be associated with coronary artery 
disease and nephropathy in patients with diabetes, which was confirmed 
by our results. 
A significant reduction in the erythrocyte deformability was observed 
between the mild CKD group and non CKD controls (EI at 3 Pa: 0.314 ± 
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0.006 vs. 0.320 ± 0.002 p<0.05). Furthermore, the CSS*ESR significantly 
differed between the moderate and mild CKD groups, and between the 
mild CKD group and healthy controls (p<0.05), suggesting that 
erythrocyte deformability and CSS*ESR could potentially be used 
clinically for identifying patients at risk of developing renal impairement.  
In terms of urine ACR, we found a negative correlation with GFR, and a 
significant difference was observed between the moderate CKD and 
healthy control groups (P value <0.05), but not between the mild CKD 
group and healthy controls. Moreover, when subjects were divided 
according to ACR, there was a significant difference in CSS*ESR 
between normal and microalbumirnuria group, which suggests its role in 
detecting nearly diabetic nephropathy. This is in accordance with a 
previous study, which was conducted on smaller number of patients. 
Patients with diabetes are required to undergo regular checkups, including 
urinary and blood analyses and ultrasonography, to detect potential 
complications. However, this requires high patient compliance and is 
associated with high costs to the patients. Thus, regular checkups for 
diabetic microcomplications are difficult in a clinical setting. If we can 
develop accurate clinical hemorheologic markers, it would be possible to 
detect early deterioration of renal function and diabetic nephropathy using 
only 5 μL blood within 30 seconds, which would result in increased 
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compliance and enable more patients to detect their diabetic complications 
earlier. 
The present study has a number of limitations. First, it is a relatively small 
study with only 105 participants; further large-scale studies are hence 
needed on the topic before any firm conclusions can be drawn. With a 
larger patient sample, the exact tendencies of the hemorheologic factors in 
the groups can be analyzed, hopefully resulting in the identification of 
parameters that will enable us to estimate nephropathy. Nevertheless, a 
major strength of the present study is that this is the first study on the 
association of diabetic nephropathy and hemorheology in comparison with 
ACR.  
In summary, examination of hemorheological factors was superior or at 
least comparable to ACR in terms of its simplicity in measurement and 
early detection of renal impairment and diabetic nephropathy in type 2 
diabetes patients. With the accumulation of clinical data and the 
establishment of appropriate reference values, hemorrheologic parameters 
may be used as screening tools for renal dysfunction and diabetic 
nephropathy 
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ABSTRACT (IN KOREAN) 
당뇨신병증의 조기 발견을 위한 혈유변학적 접근 
 
<지도교수  안 철 우> 
 
연세대학교 대학원 의학과 
 
이 서 희 
 
배경: 당뇨 환자의 경우 적혈구 변형능, 적혈구 응집성과 
같은 혈유변학적 인자의 변화가 생기게 되며, 이러한 
변화는 전혈의 점성을 증가시키며 당뇨병의 미세혈관 
합병증의 병인에 있어서 중요한 역할을 할 가능성이 
제기되고 있다. 따라서 이러한 혈유변학적 인자들을 
당뇨환자에서 측정하여, 당뇨 신병증 및 신기능 저하와의 
관련성을 조사하였다. 
방법: 105명의 제 2형 당뇨병 환자를 대상으로 사구체 
여과율에 따라서 4 그룹으로 나누어 연구를 진행하였다. 
적혈구 변형능, 적혈구응집성을 포함한 혈유변학적 
인자들을 측정하였고, 소변 알부민/크레아티닌 비율 및 
사구체여과율 저하와의 관련성을 살펴보았다. 
결과: 당뇨신병증의 단계와 적혈구 변형능, 응집성, 임계 
전단 응력, 섬유소원의 유의미한 차이가 있었다(all p<0.05). 
그 중 적혈구 변형능과 Fibrinogen/EI at 3 Pa는 정상군과 
만성신부전 2 단계에서 유의미한 차이를 보였지만, 
알부민/크레아티닌 비율에 따라서는 차이가 없었다. 또한 
다중회귀분석에서 Fibrinogen/EI at 3 Pa 은 사구체여과율을 
예측하는데 있어서 독립적인 인자로써 보여졌다(ß=-0.328, 
p<0.05).  
결론: 적혈구 변형능과 Fibrinogen/EI at 3Pa는 만성신부전의 
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초기 단계를 진단하는데 있어서 유용한 지표로 쓰일 수 
있다. 이러한 혈유변학적 인자들을 이용한다면 당뇨 
신병증을 당뇨 미세혈관 합병증의 조기진단에 큰 도움이 
될 수 있을 것이다.  
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